This study found that CEP has the potential to selectively inhibit the EGFR/PI3K/AKT pathway of stromal cells, which is expected to match the pathological characteristics of BPH dominated by matrix proliferation (Xu G. et al., 2024). Here, AKT1 is linked to benign prostatic hyperplasia.